AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Summary:
-
Small proof of concept study
-
Patient cohort had long covid
-
Ampligen well tolerated
-
Ampligen reduced fatigue more than placebo at some points in the 13 week study
-
Full press release in [the link(https://aimimmuno.com/aim-immunotech-reports-positive-topline-results-from-phase-2-study-evaluating-ampligen-for-the-treatment-of-post-covid-conditions/).
Add comment